doi: 10.1128/IAI.71.4.1864-1871.2003
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Productos relacionados: 22,90 10,90 10,90 34,90 31,90 19,47 -15% 22,90 10,97 -15% 12,90 22,80 22,50 19,47 -15% 22,90 29,90 25,90 1,50 28,90 21,06 24,90 25,90 23,90 13,90 26,90 15,90 28,90 15,90 15,90 12,90 24,46 26,90 19,47 -15% 22,90 39,50 35,90
* **Stay Hydrated:** Sip clear fluids (water, clear broth, electrolyte drinks if needed) throughout the day
This slow titration is evidence-based: clinical trials show that gradual increases improve medication tolerability and reduce dropout rates compared to faster escalation protocols
The mice were housed under pathogen-free conditions with commercial diet, water ad libitum, and 12 h light/12 h dark cycle
